ChartMill assigns a Buy % Consensus number of 82% to CALT. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-05-31 | Citigroup | Downgrade | Buy -> Neutral |
| 2024-05-28 | Stifel | Downgrade | Buy -> Hold |
| 2024-05-28 | Jefferies | Downgrade | Buy -> Hold |
| 2024-05-28 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-05-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-18 | Guggenheim | Maintains | Neutral -> Neutral |
| 2023-06-20 | HC Wainwright & Co. | Initiate | Buy |
| 2023-03-01 | Guggenheim | Initiate | Neutral |
| 2023-02-24 | Citigroup | Maintains | Buy |
| 2021-12-20 | HC Wainwright & Co. | Maintains | Buy |
13 analysts have analysed CALT and the average price target is 45.37 USD. This implies a price increase of 13.42% is expected in the next year compared to the current price of 40.0001.
The consensus rating for Calliditas Therapeutics AB (CALT) is 81.5385 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering Calliditas Therapeutics AB (CALT) is 13.